Haisco(002653)2025-04-11 09:45Financial Performance - The company's operating revenue for 2024 reached ¥3,721,349,235.28, representing a 10.92% increase compared to ¥3,355,070,109.54 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥395,455,240.18, a 34.00% increase from ¥295,111,611.86 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 45.40% to ¥132,196,788.00 from ¥242,121,310.79 in 2023[18]. - The basic earnings per share for 2024 increased by 29.63% to ¥0.35 from ¥0.27 in 2023[18]. - The total assets at the end of 2024 were ¥6,798,434,381.96, a 2.19% increase from ¥6,652,886,075.81 at the end of 2023[18]. - The net assets attributable to shareholders at the end of 2024 were ¥4,213,333,603.22, a 0.80% increase from ¥4,179,894,703.93 at the end of 2023[18]. - The cash flow from operating activities for 2024 was ¥442,045,668.69, a slight decrease of 1.68% from ¥449,578,350.12 in 2023[18]. - The weighted average return on equity for 2024 was 9.42%, up from 9.19% in 2023[18]. Dividend Distribution - The company plans to distribute a cash dividend of ¥1.35 per 10 shares, based on a total of 1,119,917,970 shares[3]. - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling 222,823,594.00 CNY for the 2023 fiscal year[176]. - For the first half of 2024, the company will distribute a cash dividend of 1.45 CNY per 10 shares, amounting to 161,547,105.65 CNY[177]. - The cash dividend for the first three quarters of 2024 is set at 1.35 CNY per 10 shares, totaling 151,188,925.95 CNY[178]. - The total cash dividend for the first three quarters of 2024 represents 100% of the profit distribution amount[178]. Revenue Breakdown - The company's total revenue for Q1, Q2, Q3, and Q4 was approximately ¥752.13 million, ¥934.51 million, ¥1.06 billion, and ¥970.11 million respectively, showing a strong performance throughout the year[22]. - Revenue from the pharmaceutical sector accounted for ¥3,692,744,368.5, which is 99.23% of total revenue, showing a growth of 10.72% compared to the previous year[69]. - The anesthetics product line generated ¥1,231,651,885.2, a significant increase of 44.96% from ¥849,663,415.80 in 2023[69]. - The western region contributed ¥1,291,774,092.2, a growth of 20.35% from the previous year, indicating strong market performance[69]. - The eastern region generated revenue of ¥581,093,056, with a gross margin of 77.18%, reflecting a 10.95% increase in revenue compared to the previous year[70]. Research and Development - The company is focusing on transitioning to innovative drug development, with significant participation in global R&D, as 31% of new drug candidates from multinational companies in 2024 originated from China[29]. - The company has established a comprehensive project management system for the entire lifecycle of drug development, from preclinical research to post-marketing studies[40]. - The company has a robust pipeline of new drug candidates, with a focus on academic marketing and product brand promotion driving rapid market penetration[44]. - The company has developed a complete technology system from early drug discovery to commercialization, emphasizing seamless integration between R&D and production[45]. - The company has established multiple specialized platforms for drug analysis, compound screening, and new drug evaluation, enhancing project management efficiency[46]. - The company plans to launch two innovative drugs, Benzenesulfonic Acid Cligabatin Capsules and Cangrelor Tablets, in 2024, achieving rapid prescription issuance within 48 hours across multiple cities[43]. - The company has completed IND applications for 4 new molecular entities in 2024, all of which have been approved for clinical trials, indicating a strong pipeline for future drug development[54]. - The company plans to leverage supportive policies for innovative drug development to accelerate its R&D pipeline[55]. Market Strategy - The company employs an innovative marketing model that integrates academic promotion, brand building, and multi-channel sales to enhance commercial capabilities[44]. - The marketing strategy focuses on innovative drugs, with the anesthetics division centered around "环泊酚" to enhance market penetration in the ICU sector[66]. - The company aims to enhance its market presence through academic promotion and brand building, focusing on key products to increase market share[127]. - The establishment of a compliant and professional academic marketing system is a priority, fostering collaboration between research, production, and marketing[127]. - The company is focused on enhancing its marketing strategy through academic promotion and brand building to increase product recognition among clinical experts[132]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[189]. - The company adheres to multiple environmental protection standards and regulations relevant to the pharmaceutical industry[190]. - The company has established a comprehensive set of guidelines for hazardous waste management and pollution control[191]. - The company is focused on enhancing its industrial waste management systems, with a target of achieving a 5.63 mg/m³ emission level for particulate matter[200]. - The company is actively pursuing compliance with GB37823 standards for air pollution control, ensuring that emissions are within regulatory limits[200]. Corporate Governance - The company maintains independence from its controlling shareholders in business operations, personnel, and financial management[145]. - The company has a clear delineation of asset ownership and does not rely on its controlling shareholders for production operations[146]. - The company operates an independent financial department with a complete financial accounting system, ensuring compliance with accounting standards[147]. - The annual shareholders meeting on May 15, 2024, had an investor participation rate of 77.45%[148]. - The first extraordinary shareholders meeting in 2024 was held on September 5, 2024, with a participation rate of 71.44%[148]. Employee and Management - The total number of employees at the end of the reporting period is 5,337, including 1,337 from the parent company and 4,000 from major subsidiaries[171]. - The professional composition includes 888 production personnel, 2,315 sales personnel, 1,576 technical personnel, 96 financial personnel, and 462 administrative personnel[171]. - The company emphasizes a compensation policy based on "efficiency first, fairness considered," aiming to create an incentive and competitive salary management system[173]. - The company has a performance evaluation group consisting of the board, strategic operations department, and human resources center for assessing senior management[159]. - The company has implemented a stock incentive plan, with the granting of restricted stock completed by September 30, 2024[182]. Financial Management - The company has received production approval for the HSK21542 injection, targeting pain management, with plans for market expansion[82]. - The company has not reported any violations in the use and disclosure of raised funds during the reporting period[119]. - The company has completed the payment of contract tail payments for new drug research and development projects, which have obtained drug registration certificates[113]. - The company has established a new special account for raised funds related to the clinical research and registration project of the new peripheral neuropathic pain treatment drug HSK16149[114]. - The company has not sold any significant assets during the reporting period[121].